A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer
NCT05130060
Completed
This phase Ib trial studies the safety and side effects of a vaccine (PolyPEPI1018 vaccine) in combination with TAS-102 in treating patients with colorectal that has spread to other parts of the body (metastatic). PolyPEPI1018 peptide vaccine is used to immunize against proteins present on the surface of tumor cells. This vaccine can activate the body's immune cells, called T cells. T cells fight infections and can also kill cancer cells. TAS-102 may help block the formation of growths that may... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2024
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Microsatellite Stable Colon Carcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Microsatellite Stable Rectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Register for Updates
Study of the Infectivity, Safety and Immunogenicity of Two Recombinant, Live-Attenuated, B/HPIV3 Vectored Vaccines Expressing the Fusion Glycoprotein of HMPV Delivered by Nasal Spray to HPIV3-Seropositive Children 24 to <60 Months of Age
NCT06546423
Recruiting
HPIV3 and HMPV are viruses that can cause breathing problems in children. The goal of this clinical trial is to look at the safety of 2 experimental HPIV3/HMPV vaccines in HPIV3-seropositive children ≥ 24 months to \< 60 months of age. Children will receive B/HPIV3/HMPV-PreF-A vaccine, B/HPIV3/HMPV-F-B365 vaccine, or placebo, and participants will not know which study product they have received. The main goals of the study are to find out whether these vaccines are well-tolerated and infectious... Read More
Gender:
ALL
Ages:
Between 24 months and 59 months
Trial Updated:
08/08/2024
Locations: CIR - Rangos, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland +3 locations
Conditions: Human Metapneumovirus, Human Parainfluenza Virus Type 3
Register for Updates
Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer
NCT03190265
Completed
The purpose of this study is to study the safety and clinical activity of nivolumab and ipilimumab in combination with either sequential administration of CY/GVAX pancreas vaccine followed by CRS-207 (Arm A) or with administration of CRS-207 alone (Arm B) in patients with pancreatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2024
Locations: Johns Hopkins SKCCC, Baltimore, Maryland
Conditions: Pancreatic Cancer
Register for Updates
A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy
NCT04847050
Completed
Background: Coronavirus disease (COVID-19) is a viral infection. It has spread rapidly across the globe. It has overwhelmed health systems. Researchers are concerned that it may undo years of progress in the reduction of cancer-specific death. They want to test a vaccine that might protect people with cancer from COVID-19. Objective: To test the safety and efficacy of a vaccine using messenger ribonucleic acid (mRNA)-1273 that may protect people with cancer from COVID-19. Eligibility: Adult... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Solid Tumor Malignancy, Hematologic Malignancy, Leukemia, Lymphoma, Multiple Myeloma
Register for Updates
An Observational Study of Moderna COVID-19 Bivalent Vaccines (Original and Omicron BA.4/BA.5) and 2023 Updated mRNA COVID-19 Vaccines (XBB.1.5)
NCT05765578
Completed
The goal of this observational study is to analyze binding antibody levels in adults in the United States (US) after receiving coronavirus disease 2019 (COVID-19) bivalent boosters (original and omicron BA.4/5) and updated COVID-19 vaccines (XBB.1.5).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2024
Locations: Science37, Culver City, California
Conditions: COVID-19
Register for Updates
A Study to Learn About a Type of Pneumococcal Vaccine With a New Ingredient (PF-07872411) Intended to Enhance the Effects of the Vaccine Which is Given to Adults
NCT05831124
Completed
The purpose of this clinical trial is to learn about a pneumococcal vaccine with a new ingredient (PF-07872411) intended to enhance the effects of the vaccine. This pneumococcal vaccine with the new ingredient may prevent the diseases caused by pneumococcal bacteria like meningitis, sepsis, ear infections and sinusitis. Meningitis is an infection in which the tissue around the brain and spine is swollen. Sepsis is a very serious infection in your blood caused by a germ (a bacteria). Sinusitis... Read More
Gender:
ALL
Ages:
Between 50 years and 64 years
Trial Updated:
07/26/2024
Locations: Indago Research & Health Center, Inc, Hialeah, Florida +8 locations
Conditions: Pneumococcal Disease
Register for Updates
RSV Vaccine Pregnancy Registry
NCT06521944
Recruiting
The research question is: What is the risk of adverse pregnancy outcomes, including preterm birth, hypertensive disorders, and other maternal and neonatal/infant outcomes, following exposure to RSV vaccine between 32 weeks, 0 days and 36 weeks, 6 days of gestation in the CorEvitas Respiratory Syncytial Virus Vaccine Pregnancy Registry (RSV-PR)? The primary study objective is to estimate the risk of (1) preterm birth and (2) hypertensive disorders following exposure to RSV vaccine between 32 week... Read More
Gender:
FEMALE
Ages:
Between 18 years and 50 years
Trial Updated:
07/23/2024
Locations: PPD, Wilmington, North Carolina
Conditions: Respiratory Syncytial Virus (RSV)
Register for Updates
Pancreatic Tumor Cell Vaccine (GVAX), Cyclophosphamide, SBRT, and FOLFIRINOX in Patients With Resected Adenocarcinoma of the Pancreas
NCT01595321
Completed
The purpose of this study is to estimate safety of GVAX Pancreas Vaccine (GVAX) with immune modulating doses of cyclophosphamide (Cy) followed by SBRT and FOLFIRINOX chemotherapy in pancreatic cancer patients after surgery.
Gender:
ALL
Ages:
Between 18 years and 76 years
Trial Updated:
07/22/2024
Locations: The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Conditions: Pancreatic Cancer
Register for Updates
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults
NCT05827978
Completed
This study includes 3 parts: Parts A, B, and C. The purpose of this study is to evaluate the immunogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2024
Locations: Pinnacle Research Group, Anniston, Alabama +102 locations
Conditions: Seasonal Influenza
Register for Updates
Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 Years
NCT05513391
Terminated
The purpose of this study was to demonstrate the non-inferior HAI immune response of quadrivalent recombinant influenza vaccine (RIV4) vs licensed Egg-Based Quadrivalent Influenza Vaccine (IIV4) for the 4 strains based on the egg-derived antigen in all participants aged 3 to 8 years and to describe the immunogenicity and safety profile of RIV4 compared to IIV4 in participants aged 3 to 8 years.
Gender:
ALL
Ages:
Between 3 years and 8 years
Trial Updated:
07/01/2024
Locations: Birmingham Pediatric Associates Site Number : 8400023, Birmingham, Alabama +30 locations
Conditions: Influenza Immunization
Register for Updates
Simultaneous RZV and aIIV4 Vaccination
NCT05007041
Completed
The overall aim of the study is to compare the safety of simultaneous Zoster Vaccine Recombinant, Adjuvanted (RZV) (SHINGRIX®) and Quadrivalent Influenza Vaccine, Adjuvanted (FLUAD®) versus simultaneous Zoster Vaccine Recombinant, Adjuvanted (RZV) (SHINGRIX®) and Fluzone® High-Dose Quadrivalent vaccine in persons age ≥65 years. A prospective, randomized, blinded clinical trial that will be conducted during the 2021/2022 and 2022/2023 influenza seasons. Over the course of these two influenza seas... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
06/28/2024
Locations: Johns Hopkins University, Baltimore, Maryland +1 locations
Conditions: Pain, Quality of Life, Injection Site Reaction, Adverse Drug Event
Register for Updates
Dendritic Cell Vaccine for Children and Adults With Sarcoma
NCT01803152
Completed
The purpose if this study is to evaluate an investigational vaccine using patient-derived dendritic cells (DC), a type of white blood cell that helps fight infections in the body, (DC) (a vaccine made out of participants' own cells and tumor) to treat sarcoma.
Gender:
ALL
Ages:
Between 1 year and 100 years
Trial Updated:
06/28/2024
Locations: University of Miami, Miami, Florida
Conditions: Sarcoma, Soft Tissue Sarcoma, Bone Sarcoma
Register for Updates